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Abstract
In recent years there has been a renewed interest concerning the ways in which the gastrointestinal tract – its
functional integrity and microbial residents – might influence human mood (e.g. depression) and behavioral
disorders. Once a hotbed of scientific interest in the early 20th century, this area lay dormant for decades, in part
due to its association with the controversial term ‘autointoxication’. Here we review contemporary findings related
to intestinal permeability, small intestinal bacterial overgrowth, lipopolysaccharide endotoxin (LPS) exposure,
D-lactic acid, propionic acid, and discuss their relevance to microbiota and mental health. In addition, we include
the context of modern dietary habits as they relate to depression, anxiety and their potential interaction with
intestinal microbiota.
Keywords: Intestinal microbiota, Autointoxication, Depression, Anxiety, Probiotics, Microbial ecology,
Lipopolysaccharide endotoxin, Diet, Intestinal permeability, Microbial ecosystems
Introduction
As outlined in Part I of this review, early 20th century
scientists and clinicians placed emphasis on the impor-
tance of the gastrointestinal tract – its functional in-
tegrity and its microbes – as an influencing factor in
depression and other mental health disorders. The in-
terest in this topic, housed under the controversial term
of autointoxication, disappeared rapidly by 1930. The
reverse-order, top-down, focus would subsequently do-
minate research for decades; i.e. depression and anxiety
as an influencing factor in the gastrointestinal disorders.
We introduce Part II by reflecting upon one of the last
articles of the autointoxication genera (1933), wherein
neuropathologist Armando Ferraro and clinical psy-
chiatrist Joseph E. Kilman of the New York Psychiatric
Institute wrote the following in Psychiatric Quarterly
journal [1]:
‘It is far from our mind to conceive that all mental
conditions have the same etiological factor, but we feel
justified in recognizing the existence of cases of mental
disorders which have as a basic etiological factor a
toxic condition arising in the gastrointestinal tract’
In 1933, with the understanding that ‘we must not for-
get here the possibility that in the future more appro-
priate and more delicate biochemical methods may
allow us to detect [circulating gut-derived toxins] in an
easier and more accurate way than we are now able to
do’, Ferraro and Kilman proposed a multi-discipline col-
laborate effort. They wanted to establish a framework
and begin with careful experimental lines of investiga-
tion. Their recommendation was to bring together ex-
perts to examine the following variables, while at the
same time taking into consideration observable changes
in animal behavior.
1. Alterations in intestinal permeability to toxins
2. The effect of synergy among potentially toxic
chemicals arising from the gastrointestinal tract
(e.g. others had only examined indole and p-cresol
individually; in preliminary experiments, Ferraro and
Kilman reported that gut-derived toxins produced
CNS toxicity at much lower doses vs. solo
administration).
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bacteriology
4. Alterations in liver and/or kidney function
5. Alterations to dietary patterns
Knowing that each of these variables could interact
with one another, Ferraro and Kilman concluded ‘All
these problems will require time and we hope to be in a
position to report on them some time in the future’. Their
paper and plans, however, lay dormant and virtually
unreferenced. History would show that their research
‘wish-list’ would remain unfulfilled for 70 years. Here, in
Part II, we will examine many lines of contemporary re-
search and integrate what is now known concerning por-
tions of Ferraro and Kilman’s framework. Threads from
various branches of medicine, with the aid of advanced
scientific technique, provide a mosaic of context that
cannot be overlooked in future gut-brain-microbiota re-
search. As we will discuss, the conundrum of interaction
between the above variables continues to hamper the
clinical relevance of experimental probiotic science in
the brain and behavioral context.
Part II – Modern studies of relevance to Gut-brain-
microbiota connection
Within our original hypotheses on the potential value of
probiotics for states of fatigue and depression [2,3], we
sewed together separate lines of emerging research from
multiple branches of medicine. The potential mechanistic
pathways we proposed are highlighted in Table 1. Most
noteworthy, perhaps, was the increasing recognition
that mental health disorders are associated with low-grade
inflammation (e.g. C-reactive protein), oxidative stress,
and the elevation of inflammatory cytokines (e.g. TNF-α,
IL-1, IL-6). Indeed, mood disturbances and fatigue could
be induced by the systemic administration of lipopolysac-
charide endotoxin (LPS) [4]. At the same time, with the
emergence of publications indicating that probiotics could
influence systemic cytokines, oxidative stress, and inflam-
matory markers upon oral consumption [5], a mood-
regulating effect seemed scientifically plausible. There was
also research around that time indicating that otherwise
non-desirable gut microbes (e.g. Campylobacter jejuni),
at quantities too low to produce a detectable immune
response, could influence animal behavior indicative of
human anxiety [6]. This suggested to us that probiotics,
either directly, or through their influence on other gut
microbes, may also play a role inp r e c i s e l yt h eo p p o s i t ed i -
rection – benefits to cognition and behavior via gut-to-
brain communication.
In the decade subsequent to the hypotheses, the ex-
pansion of direct and indirect probiotic-brain research
has been immense. A number of groups, including our
own, have published preliminary human studies showing
that orally consumed probiotic strains can indeed influ-
ence aspects of mental outlook and cognition [7-9]. The
human studies have also been supported by a variety of
elegant bench/rodent studies that have helped to shed
light on the potential pathways whereby probiotic micro-
organisms can influence brain and behavior [10]. Below
are updated discussions concerning these pathways and
the critical links between the gastrointestinal tract, its
microbial residents, and mental health. Although the gut-
microbiota-brain connection may ultimately extend clinic-
ally to diverse conditions, from autism to schizophrenia
[11,12], for the purposes of this article, the focus will lar-
gely remain on advances in depression and anxiety.
Inflammation, oxidative stress and endotoxins
Within developed nations, up to one third of all visits to
primary care clinicians involve patients with emotional
disorders, most notably anxiety and/or depressive condi-
tions [13]. As researchers explore the pathophysiology of
mood and anxiety disorders, the links between elevations
in markers of inflammation (e.g. cytokines, C-reactive
protein) and emotional disorders have grown in strength
[14]. Evidence also continues to indicate that the antioxi-
dant defense system is overwhelmed in humans with
major depressive disorder and that the burden of oxida-
tive stress and inflammation becomes a viscous cycle
[15]. Remarkably, even skin biopsy samples from depres-
sed patients (vs. matched healthy controls) show higher
levels of oxidative stress [16]. Moreover, researchers are
beginning to understand how and why inflammation
Table 1 Probiotics for fatigue and depression - proposed
pathways - adapted from Medical Hypotheses - Logan,
et al. [2] and Logan, et al. [3]
￿ Direct protection of the intestinal barrier
￿ Influence on local and systemic antioxidant status, reduction in lipid
peroxidation
￿ Direct, microbial-produced neurochemical production – e.g. GABA
￿ Indirect influence on neurotransmitter/neuropeptide production
￿ Prevention of stress-induced alterations to overall intestinal
microbiota
￿ Direct activation of neural pathways between gut and brain
￿ Limitation of inflammatory cytokine production
￿ Modulation of neurotrophic chemicals including brain-derived
neurotrophic factor
￿ Limitation of carbohydrate malabsorption
￿ Improvement of nutritional status – e.g. omega-3 fatty acids, minerals,
phytochemicals
￿ Limitation of small intestinal bacterial overgrowth
￿ Reduction of amine/uremic toxin burden
￿ Limitation of gastric/intestinal pathogens (e.g. Helicobacter pylori)
￿ Analgesic properties
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quence of depression [17]. Elevation in systemic in-
flammatory cytokines can signal the production of
inflammatory cytokines within the central nervous system
via microglia activation. Despite their critical role in neu-
ronal repair, chronic activation of microglia can com-
promise neuronal functioning by setting in motion a
cascade of inflammation and oxidative stress [18]. This,
in turn, can compromise normal intra and extracellular
neuronal communication.
Although a number of gut-derived bacterial products,
Staphylococcal enterotoxin B as one example, can in-
duce behavioral changes indicative of anxiety when ad-
ministered in the periphery, a key component of the
gut microbiota to brain connection are the increasingly
robust studies involving the systemic administration
of LPS endotoxins. LPS administration at low levels
(e.g. 0.4ng/kg) has been shown to cause acute anxiety,
depressive symptoms, cognitive deficits and increased
visceral pain sensitivity [19-23]. The LPS is a structural
portion of the external membrane of gram-negative bac-
teria, and it is estimated that humans harbor at least a
gram of LPS in the intestinal lumen. In healthy adults
there may be miniscule amounts of LPS found in blood
plasma (1-200pg/ml), indicating that the intestinal bar-
rier performs its exclusionary role with good efficiency
[24]. However, higher circulating LPS in the healthy ge-
neral population and patient groups is positively associ-
ated with abdominal obesity, higher insulin, triglycerides,
total cholesterol and other markers of cardiovascular
and diabetes disease risk [25-27]. LPS is cleared from
circulation by the liver and its enzyme alkaline phos-
phatase (AP) in particular [28]. LPS up-regulates AP ac-
tivity and induces oxidative stress in the liver, therefore
the ways in which antidepressant agents influence alka-
line phosphatase and liver detoxification is under in-
creased scrutiny [29].
Experimental investigations have made it clear that
LPS-induced peripheral cytokine elevations can alter
neuronal activity in the limbic system (e.g. increased
amygdala activity) [30,31]. As well as causing excitotoxic
neuronal overstimulation, the LPS-induced inflammation
can increase the activity of indoleamine-2,3-dioxyegenase
(IDO), an enzyme that breaks down tryptophan in the
kynurenine pathway. IDO activity has been positively cor-
related with depressive symptoms, and kynurenine itself
can increase anxiety when administered in the periphery.
The end result of endotoxemia may be decreased trypto-
phan and enhanced kynurenine availability, along with
compromised serotonergic functioning [32-34]. On the
other hand, kynurenic acid, produced by commensal in-
testinal microbiota and found in traditional foods (honey,
green vegetables, tubers), is readily absorbed from the GI
tract [35,36], and has been reported to have anxiolytic
activity when administered in the periphery [37]. Systemic
LPS can also induce brain or CNS cytokine production
and alter behavior without the necessity of systemic cyto-
kine involvement, with some research indicating a direct
LPS to CNS communication via brain endothelial cells
[38]. Indeed, systemic LPS can compromise the integrity
of the normal blood–brain barrier (BBB) and facilitate the
passage of a host of potential agents (environmental to-
xins, pathogens etc.) as well as LPS itself [39]. To make
matters worse, the ability to remove potentially harmful
neurotoxins (e.g. amyloid beta-derived neurotoxins) from
the brain through normally functioning efflux mecha-
nisms at the BBB is also compromised by LPS [40].
Among those with depression, the subsequent risk of
dementia or mild cognitive impairment is up to 2-fold
higher, and researchers continue to evaluate low-grade in-
flammation as a primary driver of cognitive decline [41].
Permeability of the blood–brain barrier and the intestinal
barrier is, at least in part, controlled by endocannabinoid
modulation. Endogenous cannabinoids are increased du-
ring inflammation (as are their receptors) in what appears
to be an adaptive process - cannabinoid binding to recep-
tors can attenuate LPS-induced blood–brain barrier per-
meability and intestinal inflammatory effects of LPS
[42,43]. It is also worth noting that in animal studies, pre-
vious experience with physical and/or psychological stress
(e.g. social defeat, tail shock) leads to an even more pro-
nounced inflammatory cytokine release subsequent to
LPS administration [44]. This suggests that in clinical po-
pulations certain individuals may be primed to experience
a greater burden of inflammation and oxidative stress
when specific agents (environmental toxins, bacterial
products, etc.) find their way into systemic circulation.
Intestinal permeability, bacterial overgrowth
Of course, an obvious pathway to increased LPS expo-
sure in the periphery would be a compromised intestinal
barrier, and recent investigations have indeed shown
signs of increased intestinal permeability in depression.
In findings reminiscent of Johnson and Goodall’s1 9 0 4
report on serum E. coli agglutination in depression [45],
new studies report that patients with major depression
(vs. healthy controls) have higher serum IgM and IgA
against a variety of commensal gut bacteria [46-48].
Moreover, in conditions where depressive symptoms are
often part of the picture – irritable bowel syndrome
(IBS), myalgic encephalomyelitis (ME, aka chronic fa-
tigue syndrome), fibromyalgia (FM), complex regional
pain syndrome, alcohol dependency, insulin resistance,
and obesity – studies involving human subjects have
shown high rates of intestinal permeability [49-53].
Ferraro and Kilman were most intrigued why, in their
experiments, certain animals of a given species were
more resilient to the systemic consequences of
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[1]. Controlling for body weight, why didn’t all animals
react in similar fashion to equivalent systemic doses of
gut-derived toxins? Seventy-seven years later, Italian re-
searchers would show that abnormal intestinal permeabi-
lity (IP) is a common finding in first-degree relatives of
those with autism (36.7% abnormal IP in those with aut-
ism, 21.2% in first-degree relatives, 4.8% in healthy con-
trols) [54]. Backing up the claims of Fenton Turck over
a century ago [55], psychological stress and splanchnic
hypoperfusion subsequent to exhaustive exercise have re-
cently been shown to increase intestinal permeability in
adults [56,57]. Obviously the finding of increased intes-
tinal permeability in over-lapping medical conditions pro-
vides clinical meaning to the LPS discussions above. In
addition to LPS, a more porous intestinal barrier allows
systemic access to food antigens (e.g. gliadin) environmen-
tal toxins (e.g. polychlorinated biphenyls etc.), exposure to
which is a further risk factor for depressive symptoms
[58,59]. Polychlorinated biphenyls can further compro-
mise the integrity of the intestinal lining and cause deficits
to the normal BBB permeability [60,61]. Meanwhile, pro-
biotics have been shown to influence removal of environ-
mental toxins from the gastrointestinal tract [62].
The early reports of low gastric acid among patients
with melancholia, discussed in Part I, have been con-
firmed by more modern investigations involving patients
with major depression [63,64]. The consequences of low
stomach acid production include small intestinal bacte-
rial overgrowth (SIBO) and further damage to the intes-
tinal barrier. Use of gastric acid-blocking medications
can provoke SIBO [65]. Clinically, SIBO sits on a wide
continuum from asymptomatic to a severe malabsorp-
tion syndrome. For many, there may be very mild gas-
trointestinal symptoms, including bloating, diarrhea,
abdominal pain, and constipation [66]. Once again,
much like intestinal permeability, SIBO has been found
in the aforementioned conditions - IBS, ME, FM, insulin
resistance, and obesity [67-70]; it is strongly associated
with depression and anxiety [71]. Interestingly, SIBO is
found in erosive esophagitis [72], yet in the prospective
treatment of gastro-esophageal reflux disease, those with
depression and/or anxiety are the least likely to respond
to proton pump inhibitors [73]. Given that SIBO and
intestinal permeability have been linked together, an
over-lap among these medical conditions should not be
surprising. Remarkably, eradication of SIBO with antimi-
crobials improves emotional symptoms and restores the
normal intestinal barrier [74]. SIBO can compromise
proper absorption of proteins, fats, carbohydrates, B vi-
tamins, and other micronutrients due to bacterial inter-
ference. Excess bacteria can successfully compete for
nutrients, produce toxic metabolites, and cause direct
injury to enterocytes in the small intestine [75,76]. All of
this could, of course, influence mood indirectly. On the
other hand, experimental studies show that psycho-
logical stress stagnates normal small intestinal transit
time, encourages overgrowth of bacteria, and compromi-
ses the intestinal barrier [77]. In animal research, diarrhea
and intestinal permeability are also reported together in
the context of SIBO and stress [78]. The oral administra-
tion of probiotics has been shown to be beneficial in the
reduction of SIBO [79]. Experimentally, an omega-3 defi-
cient diet increases SIBO, an interesting finding given the
consistent relationship between inadequate omega-3 and
depression [80].
Intestinal microbiota, diet and modernization
With an appreciation of inflammation, oxidative stress,
LPS, intestinal permeability and SIBO as background, we
can step back and examine the relevance of modern
dietary patterns in the context of gut to brain health as
mediated by microbes. Regarding the broad environmen-
tal influences on mental health, it has been shown in
preliminary research that richness in species biodiversity
(e.g. vegetation and birds) within urban environments is
positively associated with mental well-being [81,82]. The
same likely holds true regarding microbial biodiversity
within the gut. For example, a loss of bacterial biodiver-
sity is associated with GI disorders, skin conditions and
obesity [83]. Remarkably, a recent study showed that di-
minished environmental biodiversity (measured as rich-
ness of a wide variety of plant species) in the proximity
of personal residence is associated with lower genetic
biodiversity of a bacterial species (gammaproteobacteria)
on skin samples of those with atopy. This bacterial spe-
cies and its upstream genus Acinetobacter have been
specifically linked to anti-inflammatory cytokine produc-
tion [84]. It is becoming increasingly clear that indige-
nous or traditional dietary patterns are inclusive of many
bacterium species that might be considered to have pro-
biotic potential. Consider that an estimated 35% of all
lactic acid bacteria isolated from raw fruits and vegeta-
bles can survive gastric conditions [85]. In the 1980s re-
searchers made note of some significant differences in
the fecal microflora of rural Japanese vs. Canadian ur-
banites. They found higher counts of bifidobacterium
spp. and lactobacilli in the rural Japanese who main-
tained a traditional high-fiber diet rich in fermented
foods, vegetables and fish. Using culture technique,
Benno reported higher amounts of clostridia spp. in the
Canadians, yet overall, there was greater biodiversity
(more genera and species) in the rural-dwelling Japanese
[86]. Following up, his team reported on the differences
in fecal microflora among older adults residing in
Tokyo vs. elderly rural Japanese maintaining a high-
fiber traditional diet. Once again, there were higher
numbers of bifidobacterium spp. among the rural
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larly C. perfringens [87].
More recent investigations have also shown marked
differences in the fecal microbiota of western European
children vs. rural African children living in an environ-
ment resembling that of Neolithic subsistence farmers.
Using DNA sequencing of samples, researchers reported
less potentially pathogenic bacteria, yet a far greater
degree of biodiversity and microbial richness in rural
Africans living a traditional lifestyle and consuming tra-
ditional high fiber foods [88]. A separate group of
researchers has also noted distinct differences in the
bacterial groups and their functional genes (those involv-
ing metabolism of amino acids, etc.) in US adults living
in metropolitan centers vs. villagers living in Africa and
South America. Once again, the fecal microbiota of US
metropolitan adults showed far less diversity vs. villagers
in these distinct regions. Diet was reported to be the
control switch for intestinal microbiota, trumping other
influences such as hygiene [89]. Beyond the ‘hygeine hy-
pothesis’ (lack of exposure to diverse microbes increases
risk of allergies and exaggerated immune response), re-
searchers are questioning the broad implications of loss
of microbial diversity as a consequence of moderniza-
tion. DNA sequencing of stool samples in combination
with detailed dietary analysis have allowed researchers to
determine that long-term dietary patterns largely deter-
mine the main phyla of the gut microbial profile [90].
However, even short-term dietary changes can induce
species-level changes to the intestinal microbial resi-
dents, as can psychological stress [91]. Although the ad-
ministration of beneficial microbes may not have a
major impact on stable phyla, probiotic intervention
studies (as discussed later) serve to remind scientists that
species-level application of microbes cannot be overloo-
ked as clinically relevant. A single strain of lactobacillus
can improve overall microbial diversity [83], while the ad-
ministration of a single bifidobacterium strains can in-
crease the quantity of separate bifidobacterium species
and overall lactobacilli within the gut [92,93].
To date, detailed analyses of the gut microbiota of pa-
tients with major depressive disorder have not been
conducted by contemporary investigators. However, it is
worth noting that alterations to ‘normal’ (i.e. moder-
nized) human gut microbiota have been observed in the
same group of aforementioned chronic conditions asso-
ciated with a high degree of depressive symptoms – IBS,
ME, obesity and type 2 diabetes [94-98]. A growing
number of studies in both animals and humans are con-
tinuing to highlight the divergent effects of diet (fast-
food style Western diet vs. traditional dietary patterns)
on microbiota, LPS burden, and intestinal permeability
[24]. Studies show that the high-energy (high-fat, low-
fiber carbohydrates) diets typical of Western nations,
can diminish levels of bifidobacteria, increase intestinal
permeability and elevate blood LPS levels [99]. Human
research shows that adherence to a typical Western-style
diet (high fat and low-fiber carbohydrates) for one
month can elevate plasma endotoxin activity by 71%. By
contrast, a switch to a low-fat, low saturated fat, fiber-
rich diet (so-called ‘prudent’ or more traditional diet) for
one month can decrease baseline blood endotoxin acti-
vity by 38% in healthy adults [100]. A separate 24-week
study, in adults with clinical and laboratory signs of
metabolic syndrome, showed that a low fat and high
carbohydrate diet increased fecal bifidobacterium and
reduced fasting glucose compared to baseline [101]. Ani-
mal studies indicate that when fat intake is very high
(72%) there is a 2.7-fold increase in circulating LPS,
while diets with 40% fat elevate circulating LPS by 1.4-
fold [102]. Recall that circulating LPS can interfere with
BBB function, therefore it should not be surprising that
high fat (40% fat, mostly saturated fat from lard) diet
disturbed cognitive performance and increased BBB per-
meability. Compared to the control standard chow group,
the researchers discovered that the high-fat diet allowed a
systemically administered dye, one normally excluded
from the brain, into the hippocampus [103]. Separate
groups of researchers have reported similar findings of a
compromised BBB when animals are placed on Western-
style diets [104].
The implications of this research to neuropsychiatric
disorders are immense. With this as background, and
given the focus on depression in the current paper, it is
noteworthy that multiple epidemiological studies show
that adherence to healthy dietary patterns, particularly
the Mediterranean diet (similar to the prudent diet), is
associated with lowered risk of depression and anxiety
[105-108]. The reduction in risk of depression is clinically
meaningful; consider that in 5-year prospective research,
the resiliency factor of adherence to a Mediterranean and
traditional dietary patterns is between 25-30% [107,108].
However, patients with depression and fatigue are typically
far removed from traditional, prudent diets. Indeed, stress,
depressive symptoms and high levels of anxiety are char-
acteristically associated with increased frequency of fast-
food choices and over-consumption of high-energy, low
nutrient density foods [109-111]. Among the many impli-
cations of this dietary pattern in mental health, its ability
to establish an ‘inflammatory microbiome’ is now worthy
of further investigation.
To further illustrate the relevance of dietary choices in
the entire gut-brain-microbiome spectrum, consider that
more detailed analysis reveals that not all types of fats
and/or simple carbohydrates influence these end-points
(microbiota, intestinal permeability, LPS) by equal mea-
sure – for example, omega-3 oils, vs. oils rich in satu-
rated fats, may have a positive influence on the intestinal
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Conversely, the administration of bifidobacteria is asso-
ciated with higher omega-3 levels in brain cells [115]. In
other words, to what extent are the reported mental
health benefits of omega-3 fatty acids determined by resi-
dent intestinal microbiota? Among the simple sugars,
fructose administration has been shown to increase circu-
lating LPS by 40% (vs. controls, sucrose and glucose). In
this dietary sugar research, the LPS was normalized after
the administration of an antibiotic, indicating a direct mi-
crobial influence [116]. Given the massive rise in high-
fructose corn syrup (now representing 42% of all caloric
sweeteners) [117], surely we must question its role in
epidemiological studies linking overall simple sugar
consumption to depression [118,119]. LPS and the micro-
biota could certainly be connected to the fairly robust re-
lationship between fructose intolerance and depression
[120,121]. Lowered blood tryptophan levels have been ob-
served in fructose intolerance [122]; however, the new
findings on LPS are a clear indication for further research.
The intestinal microbiota may also be involved in the
potential value of dietary antioxidants to brain health.
Fiber-rich carbohydrates, including whole fruits and veg-
etables, are abundant in a variety of antioxidant phyto-
chemicals, most notably polyphenols. Researchers are
currently examining the complementary ways in which
antioxidant-rich foods and beverages influence gut
microbiota and, in turn, how select constituents of gut
microbiota influence phytochemical absorption [123-127].
For example, major dietary antioxidant sources such as
cocoa, coffee, green tea, blueberries, and curcumin have
all been linked in epidemiological studies to lowered risk
of depression and/or cognitive decline [128-132]. Mean-
while, these dietary agents have been shown in human
and animal studies to have beneficial effects on gut micro-
biota, including promoting the growth of lactobacilli and
bifidobacteria [133-137]. Curcumin was recently shown to
prevent LPS-induced intestinal permeability in an experi-
mental model, while green tea reduces LPS-induced sick-
ness behavior and BBB permeability [138-140]. Consider
also the previously mentioned research on high-fat/high-
sugar (fructose) diets and elevated circulating LPS. In hu-
man research the consumption of orange juice along with
a high-fat/high-carbohydrate (low fiber) meal prevented
elevations in circulating endotoxin, elevations that were
otherwise observed when the same meal is consumed with
either pure water or glucose in water at the same concen-
tration as found in orange juice [141]. Despite its fructose
content, orange juice may negate the detrimental effects
by virtue of its rich content of flavonoids.
Experimentally the links between these dietary influ-
ences on microbes (or microbes on the absorption of
dietary components) and mood are evident; consider, for
example, the observations that blueberry species, green
tea, curcumin, pomegranate, and resveratrol polyphe-
nolic extracts exert antidepressant activity and stress re-
siliency in animal models [142-146]. Research indicates
that once absorbed, single phenolic structures can have
subtle but meaningful effects on the breakdown of cen-
tral neurotransmitters [146]. Emerging studies also allow
for the suggestion that the behavioral benefits might be
explained, at least in part, by their phytochemical influ-
ence on minimizing the effects of LPS and promoting
lactobacilli and bifidobacteria growth at the expense of
potentially pathogenic microbes. For example, long-term
intake of honey, a feature of Paleolithic Age and tra-
ditional diets, has been shown in animal research to be
associated with decreased anxiety and cognitive decline
vs. sugar-free and sucrose controls [147]. It is worth not-
ing that honey, in addition to its broad array of antioxi-
dant phytochemicals, has been shown to negate the
effects of LPS and increase the growth of lactobacilli and
bifidobacterium [148,149].
Lactic acid bacterium-inclusive (non-dairy) fermented
foods are an important part of traditional Asian dietary
patterns, and some of the Lactobacillus strains within
these foods beverages and herbs, most notably L.
plantarum, have been shown to have significant antioxi-
dant activity, prevent intestinal permeability, and lower
the stress-induced LPS burden [150,151]. Fermented rice
products have shown antidepressant and anti-fatigue ef-
fects vs. standard rice in experimental animal models
[152]. In controlled human research, L. plantarum 299v
has been shown to improve pain in adults with IBS, and
the same strain can reduce markers of systemic oxidative
stress by 37% and markers of inflammation by 42% in
adult smokers [5,153]. In animal studies maternal L.
plantarum administration during pregnancy (and to off-
spring in early life – i.e. 6 months) increased microbial
diversity and had anti-obesity effects later on in the life
of offspring [154]. L. plantarum 299v, L. plantarum
DSM 15313 and other probiotics are currently being in-
vestigated for their ability to enhance the absorption of
active polyphenolic chemicals that would be of relevance
to brain health [155,156]. It is not our desire to belabor
the point concerning the interaction between food and
microbes; however, there are countless other compo-
nents of traditional diets that could be singled out for
relevancy. The seeds of Nigella sativa (black cumin), a
component of traditional dietaries in parts of Africa and
South Asia, provide a clear example. Nigella sativa has
been shown to protect the intestinal mucosa, suppress
the growth of potentially harmful gut microbiota, and
prevent LPS-induced depression-like behavior in animals
[157-159]. Consider also that naturally fermented goat
milk in traditional diets is higher in the protein lactofer-
rin [160], yet another agent that promotes the growth of
bifidobacterium at the expense of potentially pathogenic
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tal effects of LPS [161-163]. Oral lactoferrin reduces sys-
temic oxidative stress, and two week consumption of
lactoferrin-rich colostrum has been shown to attenuate
the intestinal permeability induced by exhaustive exer-
cise in healthy athletes [164].
Even individual nutrients such as magnesium, a min-
eral found richly in green plant foods and the intake of
which has been reported to be low in depression [165],
may be a factor. In experimental studies a magnesium-
deficient diet is associated with intestinal permeability
and quantitative changes to cecal bifidobacteria and
lactobacilli [166]. Zinc is yet another nutrient consist-
ently linked to depression when long-term intake is sub-
optimal [167], and once again it is a nutrient that can
influence the diversity of the intestinal microbiota and
intestinal permeability [168]. Magnesium and zinc are
necessary for the activity of intestinal alkaline phosphat-
ase (IAP), a critical enzyme involved in preserving the
diversity of gut microbiota and decreasing the systemic
LPS burden. IAP production itself is kept in balance by
the diversity of intestinal microbiota [169,170]. The
emerging research might therefore suggest that at least
one bridge between healthy traditional diets and mental
health includes resident microbiota. The research dis-
cussed below in the following sections of our series
should only serve to strengthen this view.
D-lactic and propionic acid – a cautionary tale
Beyond the general findings of lower bifidobacteria and
lactobacilli, a study involving ME (chronic fatigue syn-
drome) patients provides one of the most interesting
and unexplored links between gut dysbiosis and mental
health. Specifically, these researchers found significantly
higher levels of enteroccocus and streptococcus spp. in
the fecal samples of ME patients vs. controls. In particu-
lar, E. faecalis and S. sanguinis were found in higher
numbers, and upon closer examination it was found
that these two species manufacture significantly more
D-lactic acid upon glucose exposure [98]. Although a
variety of microbes in the gut, including probiotics, are
also known to produce lactic acid (L- and D- isomers), it
is the elevated production of D-lactic acid that becomes
a concern. D-lactic acid is broken down much more
slowly than L-lactic acid, and when it begins to accumu-
late in the intestine it can push absorption into the
blood. Other factors can enhance D-lactic acid absorp-
tion into the blood, most notably, LPS administration,
intestinal permeability, psychological stress, and osmotic
pressure [171,172].
Clinically, significant D-lactic acid accumulation
(i.e. that leading to metabolic acidosis) is largely viewed
as a rare concern, one primarily associated only with
short bowel syndrome. However, with the new findings
reported in ME, and separate animal studies on subtle
effects of gut-derived D-lactic acid, researchers are re-
framing the relevance of D-lactic acid producing gut mi-
crobes and carbohydrate fermentation. Indeed, animals
with excessive carbohydrate fermentation and D-lactic
acid production in the cecum exhibit anxiety, aggression
and impaired memory [173-175]. The latter study also
investigated plasma D-lactic acid and associated the
cognitive impairment with increasing blood levels of
D-lactic acid. It is noteworthy that D-lactic acid can
move through the BBB and appears to interfere with
neuronal energy supply via limitation of pyruvate avail-
ability. These novel studies involve low-grade D-lactic
acid levels in the periphery, well below that observed in
overt lactic acidosis, and the findings could be the link
between contemporary SIBO, LPS, intestinal permeabi-
lity and the historical ‘enterosthenia’. It is entirely pos-
sible that SIBO and carbohydrate intolerance (excess
undigested carbohydrate arriving at the colon) can drive
D-lactic acid production, absorption, and subsequent al-
terations in perception of fatigue, aspects of cognition
and behavior. At least one experimental study has shown
that bifidobacterial surface proteins can prevent intes-
tinal permeability and elevations in blood D-lactic acid
levels subsequent to ischemia [176].
This emerging research would also suggest that se-
lection criteria of probiotics for use in mental health
clinical trials should include strains with higher L- vs.
D-lactic acid production (e.g. strains of L. delbrueckii are
notorious producers of D-lactic acid) [177,178]. More-
over, the emerging research on D-lactic acid, as induced
by excessive fermentation, might also serve to warn in-
vestigators about the downsides of too much of a good
thing – i.e. too much prebiotic fiber could encourage the
growth of high D-lactic acid-producing species. Experi-
mental and human research shows that excess prebiotic
fiber can be an irritant to the gut barrier, increasing in-
testinal permeability [179]. Recently beta-glucans, often
touted for prebiotic activity, were shown to increase in-
testinal permeability in an ex vivo animal study [180].
These findings should be taken into consideration in
clinical trials regarding patient selection, and in particu-
lar those who might report carbohydrate intolerance or
worsening of GI symptoms upon bran or other types of
fiber consumption should be differentiated as part of
trial designs. Although it is often assumed that the eleva-
tion of intestinal propionate production via prebiotics is
a beneficial to the host, it is worth pointing out that sys-
temic propionic acid reduces locomotor activity, and
when it enters the brain it can induce a neuroinflam-
matory response and impair social behavior in animals
[181]. In short, the well-meaning lay advice to supple-
ment with prebiotics, or the wrong types of probiotics,
may have unintended consequences to sub-groups of
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It is entirely possible that large doses of prebiotics or
strains of L. delbrueckii may increase anxiety in those
with, for example, co-morbid IBS and anxiety.
Lessons from germ-free animals
The original work of Cohendy in 1912, wherein he de-
monstrated the resiliency of chickens reared in a germ-
free environment [182], takes on new meaning with
emerging studies involving germ-free mice. Studies have
recently shown that mice reared in germ-free envi-
ronments (consuming only autoclaved food) actually
displayed decreased anxiety vs. animals raised with an
intact intestinal microbiota (one without specific patho-
gens). The behavioral changes were linked to some dis-
tinct differences in neurotransmitter turnover, as well as
genetic and protein expression for receptors and neu-
ronal plasticity [183]. Moreover, the transfer of con-
ventional microbiota to germ-free animals early in life
seemed to negate the behavioral/neuronal differences,
while transfer in adulthood did not reverse the beha-
vioral signs of less anxiety in the originally germ-free
animals. Other studies have reported similar findings
[184-186]. One interpretation of the research is that
throughout evolution, colonization with gut microbiota
in early life became a critical mediator of some aspects of
brain development; i.e. communication from gut-to-brain
via microbes helped facilitate a higher level of subsequent
vigilance and threat-based surveillance, particularly in our
ability to read commensal shifts and/or the presence of
potentially pathogenic microbes. Experimentally, germ-
free animals have a compromised ability to form memo-
ries [187], and this too may reflect lower baseline vigi-
lance. Recall the earlier discussion regarding low levels of
circulating LPS among healthy individuals, therefore it is
plausible that even very low levels of LPS (sampled via
“normal” microbiota) may act as a kindling to increased
vigilance in the conventional animals. Indeed, gut com-
mensal bacteria can efficiently detect the presence of a
parasite (Toxoplasma gondii)i nt h ei n t e s t i n e ,a n di nt u r n ,
initiate signals for a defensive immune response – all this
without the parasite actually activating specific receptors
otherwise responsible for the detection of infectious pa-
thogens [188].
The behavioral signs of decreased anxiety in germ-free
animals are not necessarily a good thing, at least not in
clinical terms. The experimental studies to date have
mostly utilized the elevated plus maze (EPM) as the pri-
mary tool in objective behavioral assessment. Briefly, the
EPM is a plus-sign-shaped apparatus that is typically set
up around 2 feet off the laboratory floor; it includes two
open arms (extending planks) without walls and two
closed arms with walls and an open top. Exploration
out from the closed areas to open arms is taken as a
behavioral sign of decreased anxiety in an animal. In
controlled studies the EPM is suitable in efforts to deter-
mine if an intervention (e.g. medication) can influence
approach/avoidance behavior in animals, although even
here its universal acceptance as a means to specifically
and objectively measure anxiety has recently been called
into question [189]. In the germ-free rodent studies, as-
suming that the mice with the healthy gut microbiota
are the “otherwise well-adjusted” animals exhibiting nor-
mal baseline behavior, exploration in the open arms by
the germ-free mice can also be taken as a sign of in-
creased risk-taking; it is entirely possible that a microbe-
free gut encourages a higher level of risky behavior, one
that might put the animal in harm’s way of a predator.
In one of the studies [183] the germ-free mice explored
to the extreme ends of the open arms almost times more
often than did the conventional mice, certainly sugges-
ting a higher degree of risky behavior.
Therefore, the question remains, to what extent is
the commensal bacteria protecting us? To what extent
does it provide support in the development of an appro-
priate level of vigilance? Recall the importance of nor-
mal, healthy intestinal microbiota in launching a defense
against T. gondii [188]. Potential relationships between
T. gondii, alterations to normal intestinal microbiota,
intestinal permeability, behavioral risk-taking in ani-
mals, human schizophrenia, suicide risk, and depression
[11,190,191] is an area worthy of investigation. How
would germ-free animals react to predator odor? The
amygdala is a critical structure for legitimate threat de-
tection and vigilance, and lesions of the amygdala in pri-
mates and humans extinguish the aversion to monetary
loss [192]. Germ-free mice were noted to have decreased
N-methyl-D-aspartate (NMDA) receptor mRNA expres-
sion in the central amygdala, leading to speculation of
decreased amygdala activity in concert with decreased
anxiety [183]. It is noteworthy that activity in the central
amygdala is involved in processing the reaction to preda-
tor odor [193]. Moreover, in one study involving germ-
free mice, confinement stress produced higher levels of
plasma corticosterone in the germ-free animals vs. those
with pathogen-free microflora and in those where the
gut was inhabited by bifidobacterium infantis [184]. In
humans, a large cortisol response under stress is asso-
ciated with decision making that is in line with imme-
diate reward and high risk of punishment. In rodents
glucocorticoid elevation predicts self-administration of
psychostimulant drugs and evidence suggests that corti-
sol itself may be a driver of highly rewarding behavior at
the expense of contemplation of risk [194].
Recently investigators have examined the effects of a
Western diet (higher dietary fat, cholesterol, sugar) con-
sumed by mice during pregnancy and determined that
changes to milk quality induces systemic inflammation
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pups nursed by Western diet-consuming mothers was
even more pronounced when the parent was also raised
as germ-free [195]. This highlights that certain com-
mensal bacteria may afford a layer of protection against
the effects of a Western-diet during a delicate deve-
lopmental stage. The research also highlights that the
relationships between diet, microbiota, metabolism, in-
flammation and behavior are intertwined. Reductionist
approaches have certainly uncovered that microbiota
alone can act as a CNS-influencing entity; however,
there are a host of drawbacks in using germ-free mice,
or rodents in general, to speculate on complex human
gut-brain communications. Consider that shortly after
germ-free mice are colonized with just a single species
of commensal bacterium, researchers note marked
changes to the expression of genes that govern intestinal
permeability, nutrient absorption, blood vessel growth,
and the metabolism of environmental toxins [196] – all
of which could influence behavior via LPS and other
pathways. A single strain of bifidobacterium, for ex-
ample, can elevate blood tryptophan levels in animals,
meanwhile tryptophan depletion during lactation can
interact with stress hormones to increase anxiety later in
life [197].
Interesting studies with germ-free animals have little
to no clinical frame of reference in mental health - i.e.
humans do not live with a sterile GI tract while consum-
ing exclusively autoclaved food; however, they do indi-
cate that developmentally our resident microbiota, or
the absence thereof, can have a long-standing influence
on brain functioning and behavior. Researchers might
ponder if long-term mental health consequences could
be associated with the routine prophylactic use of broad-
spectrum antimicrobials among pre-term infants. This
practice, one that has been questioned recently [198], sets
up a pseudo-germ-free situation in premature infants, and
it can now be yet one more factor to consider in the link
between pre-term birth and mental illness. Recently, a
large epidemiological study using the Swedish Medical
Birth Register – 1.3 million people - has found that pre-
mature birth is associated with a 30% higher risk of de-
pression and a 270% increase in bipolar depression later in
life [199]. At some point in the future, with more detailed
investigations, the germ-free studies may be of relevance
in bridging the research on the immune benefits of pre-
natal exposure to probiotics, and on the other side, the in-
creased risk of serious mental illness (in adult offspring)
subsequent to infection during pregnancy [200]. Of
course, there is also the issue of intestinal microbiota
and their effects on the elimination of environmental
toxins. When animals are exposed to low doses of bis-
phenol A (BPA) during gestation, lactation and nursing,
there are subsequently marked increases in later-life
anxiety accompanied by alterations in gene expression
within the amygdala [201]. With the recent discovery that
oral probiotics co-administered with BPA can dramatically
reduce the systemic burden of this and other environ-
mental toxins (increasing elimination via fecal route), it
becomes difficult to view the ‘real world’ gut-brain con-
nection in germ-free isolation. The influence of probiotic
administration on both the developing immune system
and metabolism during the introduction of foods (weaning
diet) is an exciting area of research, with preliminary re-
sults indicating long-term systemic effects [202].
The stage is set
The research discussed here in Part II can be considered
contextual; before examining more clinically relevant in-
vestigations on behavior and microbiota, it seems vital
to underscore the fact that any discussion of microbiota
and mental health, or probiotics as an intervention in
behavioral medicine, is not akin to discussions of al-
prazolam, fluoxetine, etc. There are a myriad of ways in
which the microbes of the intestinal tract may interact
with environmental factors, most notably those of the
dietary. As described here in Part II, some of Ferraro
and Kilman’s 1933 ‘wish list’ of research has been ini-
tiated, including the effects of intestinal permeability and
dietary alterations in relation to microbes and mental
health. In Part III we will turn our attention to the other
aspects, including purposeful alterations of the intestinal
microbiota (dysbiosis), the unresolved effects of intestinal-
derived toxins, and the experimental and clinical applica-
tion of factors of bacteriology (probiotics).
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